2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOX
2023
Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
Chen E, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G, Group O. Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma. Cancer Medicine 2023, 12: 12986-12995. PMID: 37132281, PMCID: PMC10315770, DOI: 10.1002/cam4.5971.Peer-Reviewed Original ResearchConceptsNab-paclitaxelNeoadjuvant treatmentDefinitive resectionResection rateAdverse eventsPancreatic adenocarcinomaOpen-label phase 2 trialNode-positive pancreatic cancerLong-course chemoradiationNab-paclitaxel 125Neoadjuvant treatment strategiesOperable pancreatic adenocarcinomaRadiographic response rateCommon adverse eventsR0 resection ratePhase 2 studyPhase 2 trialProgression-free survivalProspective interventional trialNegative surgical marginsTreatment completion ratesPancreatic ductal adenocarcinomaIntensity-modulated radiationGemcitabine 1000Positive nodes
2020
Neoadjuvant Chemotherapy or Chemoradiotherapy Does Not Increase Early and Late Post-operative Complication Rates Following Definitive Resection for Pancreatic Ductal Adenocarcinoma
Deig C, Stratton A, Trone K, Beneville B, Liu A, Kanwar A, Bassale S, Chen Y, Grossblatt-Wait A, Attia F, Sheppard B, Keith D, Chen E, Lopez C, Billingsley K, Gilbert E, Nabavizadeh N, Thomas C, Grossberg A. Neoadjuvant Chemotherapy or Chemoradiotherapy Does Not Increase Early and Late Post-operative Complication Rates Following Definitive Resection for Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e606-e607. DOI: 10.1016/j.ijrobp.2020.07.1845.Peer-Reviewed Original ResearchPhase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
Chen E, Tormoen G, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G. Phase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma. Journal Of Clinical Oncology 2020, 38: 697-697. DOI: 10.1200/jco.2020.38.4_suppl.697.Peer-Reviewed Original ResearchGemcitabine/nab-paclitaxelPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaPre-operative therapyPre-operative treatmentNab-paclitaxelPancreatic resectionDuctal adenocarcinomaBorderline resectable pancreatic ductal adenocarcinomaSingle-arm phase II trialNab-paclitaxel chemotherapyPositive clinical nodesPhase II studyR0 resection ratePhase II trialNegative surgical marginsRelapse-free survivalMicro-metastatic diseaseIntensity-modulated radiation therapyGemcitabine 1000II trialPrimary endpointResection rateSecondary endpointsII study
2011
A Nomogram for Predicting the Benefit of Adjuvant Therapy for Resected Pancreatic Ductal Adenocarcinoma
Bicquart C, Youssef R, Wissel A, Sheppard B, Billingsley K, Thomas C, Wang S. A Nomogram for Predicting the Benefit of Adjuvant Therapy for Resected Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s561. DOI: 10.1016/j.ijrobp.2011.06.887.Peer-Reviewed Original ResearchResected Pancreatic Ductal AdenocarcinomaPancreatic ductal adenocarcinomaAdjuvant therapyDuctal adenocarcinomaAdenocarcinomaTherapyNomogram
2009
Effect of Chemoradiation on Survival of Resected Pancreatic Ductal Adenocarcinoma with Close or Positive Margins
Bicquart C, Youssef R, Sheppard B, Corless C, Billingsley K, Thomas C. Effect of Chemoradiation on Survival of Resected Pancreatic Ductal Adenocarcinoma with Close or Positive Margins. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s291-s292. DOI: 10.1016/j.ijrobp.2009.07.671.Peer-Reviewed Original ResearchResected Pancreatic Ductal AdenocarcinomaEffects of chemoradiationPancreatic ductal adenocarcinomaPositive marginsDuctal adenocarcinomaChemoradiation